The Administrative core will be responsible for the overall management of this HIVRAD. This Core will be responsible for interacting with DAIDS Program Officer and Staff as required by the funding mechanism as a multi-project cooperative agreement between our team and the NIH. The Core will coordinate all aspects of routine program management on administrative, financial, and regulator issues. The Administrative Core will also organize and interact with external advisors, and host annual external reviews. This Core has the following four Specific Aims: 1- To coordinate the interactions a) among scientists from different institutions included in the current program and b) between our team and Scientific Advisory Board members and NIH personnel regarding efficient implementation of the proposed plans and projects. 2- To oversee budgetary matters, including review and approval of subcontractual agreements, monitoring of monthly expenses and preparation of various reports. 3- To develop an Intellectual Property plan and provide logistical support for intellectual property filings and negotiations 4- To coordinate publications and presentations of results arising from these studies.

Public Health Relevance

This program involves scientists working at 4 different locations throughout the US and 2 sites in South Africa. For this program to operate efficiently and productively, a centralized Administrative oversight is essential. This will be provided by Dr. Pinter and his assistants, who will be responsible for coordinating communication between the participating scientists, NIH Program Officials, and internal and external Scientific Advisory Committees, and will facilitate other scientific, legal and logistical issues that may arise.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RB-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Rutgers University
United States
Zip Code
Salomon, Aidy; Krachmarov, Chavdar; Lai, Zhong et al. (2014) Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking. Virology 448:363-74
Derdeyn, Cynthia A; Moore, Penny L; Morris, Lynn (2014) Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr Opin HIV AIDS 9:210-6
Moore, Penny L; Sheward, Daniel; Nonyane, Molati et al. (2013) Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol 87:4882-94
Murphy, Megan K; Yue, Ling; Pan, Ruimin et al. (2013) Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog 9:e1003173
Wibmer, Constantinos Kurt; Bhiman, Jinal N; Gray, Elin S et al. (2013) Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 9:e1003738
Sethi, Anurag; Tian, Jianhui; Derdeyn, Cynthia A et al. (2013) A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein. PLoS Comput Biol 9:e1003046
Moore, Penny L; Gray, Elin S; Sheward, Daniel et al. (2011) Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol 85:3128-41
Gray, Elin S; Madiga, Maphuti C; Hermanus, Tandile et al. (2011) The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 85:4828-40
Krachmarov, Chavdar; Lai, Zhong; Honnen, William J et al. (2011) Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities. J Virol 85:10730-40